Taigen Biopharmaceuticals Co. (Beijing), Ltd.

Main study objectives To evaluate the clinical efficacy of TG-1000 versus placebo in adult and adolescent subjects with acute influenza virus infection without complications. Secondary study objectives 1. To evaluate the antiviral effect of TG-1000 versus placebo in adult and adolescent subjects with acute influenza virus infection without complications. 2. To evaluate the differences in clinical symptom outcomes and influenza-related complications in adult and adolescent subjects treated with TG-1000 versus placebo.

To evaluate the in vivo material balance of [14C]TG-1000 after a single oral dose of [14C]TG-1000 in healthy adult male subjects in China, reveal the overall pharmacokinetic characteristics of TG-1000 in humans, and provide a reference for the rational use of the drug.

To evaluate the clinical and microbiological efficacy and safety of oral nemonoxacin malate in the treatment of community-acquired pneumonia in adults, and to understand the population pharmacokinetic (PPK) characteristics of continuous oral nemonoxacin malate in adult patients with community-acquired pneumonia and evaluate the results of pharmacokinetic (PK)/pharmacodynamic (PD) analysis.